Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway

Nature Medicine

Volumn 5, Issue 12, 1999, Pages 1370-1374

  Puglielli, Maryann T ^a   Browning, Jeffrey L ^b   Brewer, Avery W ^c   Schreiber, Robert D ^d   Shieh, Wun Ju ^e   Altman, John D ^a   Oldstone, M B A ^f   Zaki, Sherif R ^e   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIOGEN   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HISTOLOGY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY FAILURE; SHOCK; VIRUS PATHOGENESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOTOXIN BETA RECEPTOR; MALE; MICE; MICE, INBRED NZB; RECEPTORS, TUMOR NECROSIS FACTOR; RESPIRATORY INSUFFICIENCY; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 0032752092     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/70938     Document Type: Article

References (34)

1. Lacy, M.D. & Smego, R.A. Viral hemorrhagic fevers. Adv. Pediatr. Infect. Dis. 12, 21-53 (1996).
2. Peters, C.J. in Viral Pathogenesis (ed. Nathanson, N.) 779-799 (Lippincott-Raven, Philiadelphia, 1997).
3. No author given. Hantavirus pulmonary syndrome - Colorado and New Mexico, 1998. Morbid. Mortal. Weekly Report 47, 449-452 (1998).
4. Toro, J. et al. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg. Infect. Dis. 4, 687-694 (1998).
5. Zaki, S.R. et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am. J. Pathol. 146, 552-579 (1995).
6. Zaki, S.R. et al. Retrospective diagnosis of hantavirus pulmonary syndrome, 1978-1993: implications for emerging infectious diseases. Arch. Pathol. Lab. Med. 120, 134-139 (1996).
7. Nolte, K.B. et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Hum. Pathol. 26, 110-120 (1995).
8. Hallin, G.W. et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit. Care Med. 24, 252-258 (1996).
9. Talal, N. & Steinberg, A.D. The pathogenesis of autoimmunity in New Zealand black mice. Curr. Top. Microbiol. Immunol. 64, 79-103 (1974).
10. Ahmed, R. & Oldstone, M.B. Organ-specific selection of viral variants during chronic infection. J. Exp. Med. 167, 1719-1724 (1988).
11. Matloubian, M., Kolhekar, S.R., Somasundaram, T. & Ahmed, R. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 67, 7340-7349 (1993).
12. Sheehan, K.C., Ruddle, N.H. & Schreiber, R.D. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J. Immunol. 142, 3884-3893 (1989).
13. Wong, G.H. & Goeddel, D.V. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 323, 819-22 (1986).
14. Beutler, B., Milsark, I.W. & Cerami, A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869-871 (1985).
15. Mackay, F. et al. Cytotoxic activities of recombinant soluble murine lymphotoxin-alpha and lymphotoxin-alpha beta complexes. J. Immunol. 159, 3299-3310 (1997).
16. Crowe, P.D. et al. A lymphotoxin-beta-specific receptor. Science 264, 707-710 (1994).
17. Hober, D. et al. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am. J. Trop. Med. Hyg. 48, 324-231 (1993).
18. Bethell, D.B. et al. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J. Infect. Dis. 177, 778-782 (1998).
19. Force, W.R. et al. Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression. J. Immunol. 155, 5280-5288 (1995).
20. Miller, G.T. et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J. Exp. Med. 178, 211-222 (1993).
21. Browning, J.L. et al. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J. Immunol. 154, 33-46 (1995).
22. Abe, Y. et al. Studies of membrane-associated and soluble (secreted) lymphotoxin in human lymphokine-activated T-killer cells in vitro. Lymphokine Cytokine Res. 11, 115-121 (1992).
23. Ware, C.F., Crowe, P.D., Grayson, M.H., Androlewicz, M.J. & Browning, J.L. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J. Immunol. 149, 3881-3888 (1992).
24. Browning, J.L. et al. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72, 847-856 (1993).
25. Mauri, D.N. et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8, 21-30 (1998).
26. Montgomery, R.I., Warner, M.S., Lum, B.J. & Spear, P.G. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87, 427-436 (1996).
27. Sayer, W.J., Entwhisle, G., Uyeno, B. & Bignall, R.C. Cortisone therapy of early epidemic hemorrhagic fever: a preliminary report. Ann. Int. Med. 42, 839-851 (1955).
28. Mertz, G.J., Hjelle, B.L., Williams, T.M. & Koster, F.T. Host responses in the hantavirus cardiopulmonary syndrome, in Emergence and Control of Rodent-Borne Viral Diseases 43, p.43 (Marcel Merieux Foundation, Annecy, France, 1998).
29. Ahmed, R., Salmi, A., Butler, L.D., Chiller, J.M. & Oldstone, M.B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160, 521-540 (1984).
30. Dialynas, D.P. et al. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131, 2445-2451 (1983).
31. Sourdive, D.J. et al. Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J. Exp. Med 188, 71-82 (1998).
32. Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
33. Zajac, A.J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
34. Murali-Krishna, K. et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8, 177-187 (1998).